Vaccinex, Inc. (NASDAQ:VCNX – Get Free Report)’s share price shot up 1% on Monday . The stock traded as high as $1.06 and last traded at $1.06. 1,535 shares were traded during mid-day trading, a decline of 52% from the average daily volume of 3,211 shares. The stock had previously closed at $1.05.
Vaccinex Trading Up 1.0%
The company has a market cap of $2.76 million, a price-to-earnings ratio of -0.02 and a beta of 1.10. The business has a fifty day moving average of $1.05 and a two-hundred day moving average of $1.01.
About Vaccinex
Vaccinex, Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting oncology and neurodegenerative diseases. Headquartered in Rochester, New York, Vaccinex harnesses its proprietary human antibody platform to modulate the semaphorin 4D (SEMA4D) pathway, a mechanism implicated in tumor immune evasion and neuroinflammatory processes. Its lead asset, pepinemab (VX15/2503), is an investigational monoclonal antibody designed to bind and block SEMA4D, thereby promoting immune cell infiltration in tumors and supporting neural repair in degenerative disorders.
In oncology, Vaccinex has advanced pepinemab through Phase 2 trials in solid tumors and hematologic malignancies, exploring its potential to enhance the efficacy of established checkpoint inhibitors.
Recommended Stories
- Five stocks we like better than Vaccinex
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.
